Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

Table 3 Eradication rates of each treatment group

Analysis	14d-EA group	14d-B-quadruple group	Difference from 14d-B-quadruple group (adjusted 95%CI for difference)	P value for difference1	P value for non-inferiority2	14d-VA group	14d-VAC group	Difference from 14d-VAC group (adjusted 95%CI for difference)	P value for difference3	P value for non-inferiority4
ITT (%)	70.59 (156/221)	83.49 (182/218)	-12.90 [-20.67, -5.13]	0.001a	0.7676	84.15 (154/183)	83.15 (153/184)	1.00 [-6.56, 8.57]	0.795	0.0022b
95%CI (%)	64.53-76.64	78.52-88.45				78.81-89.49	77.69-88.61
mITT (%)	92.86 (156/168)	98.38 (182/185)	-5.52 [-9.82, -1.22]	0.01a	0.0206b	96.25 (154/160)	92.73 (153/165)	3.52 [-1.41, 8.46]	0.165	< 0.0001b
95%CI (%)	88.92-96.79	96.54-100.00				93.27-99.23	88.72-96.73
PP (%)	93.94 (155/165)	98.38 (182/185)	-4.44 [-8.51, - 0.37]	0.028a	0.0037 b	96.75 (149/154)	93.75 (150/160)	3.00 [-1.68, 7.68]	0.212	< 0.0001b
95%CI (%)	90.26-97.62	96.54-100.00				93.92-99.58	89.96-97.54

¹P values were obtained from two-sided comparisons of the difference between the 14d-EA group and the 14d-B-quadruple group.

²P values were obtained from one-sided test comparisons of non-inferiority between the 14d-EA group and the 14d-B-quadruple group.

³P values were obtained from two-sided comparisons of the difference between the 14d-VA group and the 14d-VAC group.

⁴P values were obtained from one-sided test comparisons of non-inferiority between the 14d-VA group and the 14d-VAC group.

^aP < 0.05.

^bP < 0.025.

ITT: Intention-to-treat; mITT: Modified intention-to-treat; PP: Per-protocol; EA: Esomeprazole-amoxicillin; B-quadruple: Esomeprazole-amoxicillin-clarithromycin-bismuth; VA: Vonoprazan-amoxicillin; VAC: Vonoprazan-amoxicillin-clarithromycin.